Results 41 to 50 of about 11,143 (189)

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

Update on the Pathophysiology, Aetiology and Management of Central Sleep Apnoea

Respirology, EarlyView.
ABSTRACT Central sleep apnoea (CSA) of the periodic breathing type occurs during the transition between wakefulness and stage 1 and 2 non‐REM sleep. In adults at sea level, it occurs most commonly due to advanced heart failure (HF) or chronic opioid use and in ~5% of obstructive sleep apnoea patients initiating CPAP.
Sahan D. Chandrasekara, Matthew T. Naughton   +1 more
wiley   +1 more source

Shear‐Responsive Red Blood Cell Carriers for Targeted Drug Delivery to Constricted Arteries

Small, EarlyView.
Red blood cells are harnessed as mechanoresponsive carriers that exploit the elevated shear stress of stenotic arteries to transiently open membrane pores and release encapsulated therapeutics selectively at sites of arterial narrowing. By coupling vascular hemodynamics with RBC membrane mechanics, a hemodynamically activated platform for localized ...
Danielle Nemcovsky Amar, Rukiye Tuna, Tirosh Mekler, Merav Belenkovich, Dmitry Korneyev, Yevgeniy Kreinin, Anat Glozman, Josué Sznitman, Donald E. Ingber, Zixiang Leonardo Liu, Netanel Korin   +10 more
wiley   +1 more source

Percutaneous Intervention of LVAD Outflow Graft Obstruction and Thrombosis

Methodist DeBakey Cardiovascular Journal
Left ventricular assist devices serve as a salvage therapy for patients with advanced heart failure. Complications such as thrombosis and obstruction can lead to acute device malfunction, posing significant clinical risks. A multidisciplinary approach is
Andrew Takla, Fahad Eid, Mostafa Elbanna, Mohamed Magdi Eid, Akshay Joshi, Abdallah Bitar, Ryan Lydon, Scott Feitell   +7 more
doaj   +1 more source

Patient-specific, echocardiography compatible flow loop model of aortic valve regurgitation in the setting of a mechanical assist device

Frontiers in Cardiovascular Medicine, 2023
BackgroundAortic regurgitation (AR) occurs commonly in patients with continuous-flow left ventricular assist devices (LVAD). No gold standard is available to assess AR severity in this setting.
Mahwash Kassi, Stefano Filippini, Eleonora Avenatti, Susan Xu, Susan Xu, Kinan Carlos El-Tallawi, Clara I. Angulo, Marija Vukicevic, Marija Vukicevic, Stephen H. Little   +9 more
doaj   +1 more source

Device‐Induced Blood Damage in Pump‐Assisted Circulation: A Comparative Study of HeartMate III and BrioVAD Pumps

Artificial Organs, EarlyView.
Shear‐induced blood damage—including hemolysis, platelet and neutrophil injury, and von Willebrand factor (vWF) degradation—was evaluated for the BrioVAD and HM3 using an in vitro circulatory loop under clinically relevant conditions. Across 15 biomarkers (n > 6 per group), no significant differences were observed between the two devices.
Wenji Sun, Kiersten P. Clark, Douglas Tran, John C. Vandenberge, Nancy Kim, Shigang Wang, Anik Tarafder, Randy Perez, Bartley P. Griffith, Dong Han   +9 more
wiley   +1 more source

Mechanistic assessment and ablation of left ventricular assist device related ventricular tachycardia in patients with severe heart failure

Frontiers in Physiology, 2023
Aims: Left-ventricular-assist-devices (lvad) are an established treatment for patients with severe heart failure with reduced ejection fraction (HF) and reduce mortality.
Felix Hohendanner, Felix Hohendanner, Felix Hohendanner, Matthias Bock, Julian Keznickl-Pulst, Vesna Furundzija, Vesna Furundzija, Sebastian Scholz, Doreen Schöppenthau, Doreen Schöppenthau, Yuriy Hrytsyna, Yuriy Hrytsyna, Volkmar Falk, Volkmar Falk, Volkmar Falk, Volkmar Falk, Burkert Pieske, Gerhard Hindricks, Gerhard Hindricks, Evgenij Potapov, Evgenij Potapov, Jin-Hong Gerds-Li, Jin-Hong Gerds-Li   +22 more
doaj   +1 more source

The Role of Patients' Treatment Expectations in Ventricular Assist Device Support: Results From a Convergent Mixed Methods Study

Artificial Organs, EarlyView.
This mixed methods study aimed to: (i) identify treatment expectations held by individuals with a ventricular assist device (VAD), (ii) assess the extent to which these expectations have been met, and (iii) examine how treatment expectations relate to VAD‐specific health‐related quality of life (HRQoL) ABSTRACT Objectives Treatment expectations ...
Simon Felix Zerth, Bernd Niemann, Miriam Salzmann‐Djufri, Sandra Semmig‐Könze, Katharina Tigges‐Limmer, Yvonne Brocks, Monika Sadlonova, Anna Markser, Tanja Zimmermann, Lara Kristin Oldach, Stefan Salzmann   +10 more
wiley   +1 more source

The Use of a Left Ventricular Assist Device (LVAD) as a Modern Treatment Option for End-Stage Chronic Heart Failure: Clinical Characteristics, Complications, and Short-Term Outcomes

Juvenis Scientia
Introduction. Chronic heart failure (CHF) is one of the leading causes of death worldwide. Although guideline-directed pharmacotherapy can alleviate symptoms, it cannot restore the heart’s pump function.
Timofeev, E. V., Olifirenko, I. S., Zaripov, B. I., Platonova, N. A., Suvorova, A. I.   +4 more
doaj   +1 more source

Efficacy of Antimicrobial Silver‐Plated Dressings Compared to Usual Care in Preventing Left Ventricular Assist Device Driveline Infections

Artificial Organs, EarlyView.
Integrating silver‐plated wound dressings into DLES care presents a safe and effective strategy for DLI prevention. Key findings include a 100% infection‐free rate in the Silverlon group, no NPWT and hospital readmission in the Silverlon group, and no severe DESTINE stages (3, 4) in the Silverlon group.
Barbara Veiter, Martina Socha, Christiane Marko, Nesibe Seyda Colak, Alexandra Kuhn, Hebe Al Asadi, Julia Riebandt, Roxana Moayedifar, Daniel Zimpfer, Thomas Schlöglhofer   +9 more
wiley   +1 more source